vs

Side-by-side financial comparison of Aclaris Therapeutics, Inc. (ACRS) and Align Technology (ALGN). Click either name above to swap in a different company.

Align Technology is the larger business by last-quarter revenue ($1.0B vs $1.3M, roughly 808.9× Aclaris Therapeutics, Inc.). Align Technology runs the higher net margin — 13.0% vs -1528.6%, a 1541.5% gap on every dollar of revenue. On growth, Align Technology posted the faster year-over-year revenue change (5.3% vs -85.9%). Align Technology produced more free cash flow last quarter ($187.3M vs $-13.2M). Over the past eight quarters, Align Technology's revenue compounded faster (2.5% CAGR vs -26.5%).

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for immunological, inflammatory, and dermatological diseases. Its pipeline includes candidates for unmet needs like alopecia areata and vitiligo, serving global patient groups.

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandib...

ACRS vs ALGN — Head-to-Head

Bigger by revenue
ALGN
ALGN
808.9× larger
ALGN
$1.0B
$1.3M
ACRS
Growing faster (revenue YoY)
ALGN
ALGN
+91.2% gap
ALGN
5.3%
-85.9%
ACRS
Higher net margin
ALGN
ALGN
1541.5% more per $
ALGN
13.0%
-1528.6%
ACRS
More free cash flow
ALGN
ALGN
$200.4M more FCF
ALGN
$187.3M
$-13.2M
ACRS
Faster 2-yr revenue CAGR
ALGN
ALGN
Annualised
ALGN
2.5%
-26.5%
ACRS

Income Statement — Q4 2025 vs Q4 2025

Metric
ACRS
ACRS
ALGN
ALGN
Revenue
$1.3M
$1.0B
Net Profit
$-19.8M
$135.8M
Gross Margin
58.9%
65.3%
Operating Margin
-1755.5%
14.8%
Net Margin
-1528.6%
13.0%
Revenue YoY
-85.9%
5.3%
Net Profit YoY
79.5%
30.8%
EPS (diluted)
$-0.16
$1.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACRS
ACRS
ALGN
ALGN
Q4 25
$1.3M
$1.0B
Q3 25
$3.3M
$995.7M
Q2 25
$1.8M
$1.0B
Q1 25
$1.5M
$979.3M
Q4 24
$9.2M
$995.2M
Q3 24
$4.3M
$977.9M
Q2 24
$2.8M
$1.0B
Q1 24
$2.4M
$997.4M
Net Profit
ACRS
ACRS
ALGN
ALGN
Q4 25
$-19.8M
$135.8M
Q3 25
$-14.6M
$56.8M
Q2 25
$-15.4M
$124.6M
Q1 25
$-15.1M
$93.2M
Q4 24
$-96.6M
$103.8M
Q3 24
$-7.6M
$116.0M
Q2 24
$-11.0M
$96.6M
Q1 24
$-16.9M
$105.0M
Gross Margin
ACRS
ACRS
ALGN
ALGN
Q4 25
58.9%
65.3%
Q3 25
83.7%
64.2%
Q2 25
71.0%
69.9%
Q1 25
65.2%
69.5%
Q4 24
92.3%
70.0%
Q3 24
85.0%
69.7%
Q2 24
77.4%
70.3%
Q1 24
66.3%
70.0%
Operating Margin
ACRS
ACRS
ALGN
ALGN
Q4 25
-1755.5%
14.8%
Q3 25
-519.8%
9.7%
Q2 25
-1035.9%
16.1%
Q1 25
-1242.9%
13.4%
Q4 24
-1082.3%
14.5%
Q3 24
-240.9%
16.6%
Q2 24
-464.7%
14.3%
Q1 24
-789.4%
15.5%
Net Margin
ACRS
ACRS
ALGN
ALGN
Q4 25
-1528.6%
13.0%
Q3 25
-443.0%
5.7%
Q2 25
-868.3%
12.3%
Q1 25
-1036.8%
9.5%
Q4 24
-1048.3%
10.4%
Q3 24
-174.6%
11.9%
Q2 24
-397.2%
9.4%
Q1 24
-706.5%
10.5%
EPS (diluted)
ACRS
ACRS
ALGN
ALGN
Q4 25
$-0.16
$1.88
Q3 25
$-0.12
$0.78
Q2 25
$-0.13
$1.72
Q1 25
$-0.12
$1.27
Q4 24
$-1.21
$1.40
Q3 24
$-0.11
$1.55
Q2 24
$-0.15
$1.28
Q1 24
$-0.24
$1.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACRS
ACRS
ALGN
ALGN
Cash + ST InvestmentsLiquidity on hand
$20.0M
$1.1B
Total DebtLower is stronger
Stockholders' EquityBook value
$103.1M
$4.0B
Total Assets
$160.5M
$6.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACRS
ACRS
ALGN
ALGN
Q4 25
$20.0M
$1.1B
Q3 25
$25.3M
$1.0B
Q2 25
$25.4M
$901.2M
Q1 25
$30.4M
$873.0M
Q4 24
$24.6M
$1.0B
Q3 24
$47.7M
$1.0B
Q2 24
$22.8M
$761.4M
Q1 24
$35.8M
$865.8M
Stockholders' Equity
ACRS
ACRS
ALGN
ALGN
Q4 25
$103.1M
$4.0B
Q3 25
$120.1M
$4.0B
Q2 25
$131.7M
$3.9B
Q1 25
$144.1M
$3.8B
Q4 24
$155.6M
$3.9B
Q3 24
$130.2M
$3.9B
Q2 24
$133.8M
$3.8B
Q1 24
$142.0M
$3.8B
Total Assets
ACRS
ACRS
ALGN
ALGN
Q4 25
$160.5M
$6.2B
Q3 25
$175.5M
$6.2B
Q2 25
$189.1M
$6.2B
Q1 25
$198.1M
$6.1B
Q4 24
$220.3M
$6.2B
Q3 24
$182.4M
$6.4B
Q2 24
$161.1M
$6.2B
Q1 24
$174.1M
$6.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACRS
ACRS
ALGN
ALGN
Operating Cash FlowLast quarter
$-13.1M
$223.2M
Free Cash FlowOCF − Capex
$-13.2M
$187.3M
FCF MarginFCF / Revenue
-1015.8%
17.9%
Capex IntensityCapex / Revenue
1.9%
3.4%
Cash ConversionOCF / Net Profit
1.64×
TTM Free Cash FlowTrailing 4 quarters
$-47.2M
$490.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACRS
ACRS
ALGN
ALGN
Q4 25
$-13.1M
$223.2M
Q3 25
$-10.9M
$188.7M
Q2 25
$-10.0M
$128.7M
Q1 25
$-13.1M
$52.7M
Q4 24
$-8.9M
$286.1M
Q3 24
$22.0M
$263.7M
Q2 24
$-12.3M
$159.8M
Q1 24
$-20.8M
$28.7M
Free Cash Flow
ACRS
ACRS
ALGN
ALGN
Q4 25
$-13.2M
$187.3M
Q3 25
$-11.0M
$169.0M
Q2 25
$-10.0M
$107.2M
Q1 25
$-13.1M
$27.4M
Q4 24
$263.1M
Q3 24
$233.9M
Q2 24
$-12.3M
$106.4M
Q1 24
$-20.9M
$19.3M
FCF Margin
ACRS
ACRS
ALGN
ALGN
Q4 25
-1015.8%
17.9%
Q3 25
-332.1%
17.0%
Q2 25
-563.5%
10.6%
Q1 25
-900.3%
2.8%
Q4 24
26.4%
Q3 24
23.9%
Q2 24
-446.0%
10.3%
Q1 24
-873.6%
1.9%
Capex Intensity
ACRS
ACRS
ALGN
ALGN
Q4 25
1.9%
3.4%
Q3 25
0.7%
2.0%
Q2 25
1.2%
2.1%
Q1 25
3.0%
2.6%
Q4 24
0.0%
2.3%
Q3 24
0.0%
3.0%
Q2 24
0.5%
5.2%
Q1 24
5.6%
0.9%
Cash Conversion
ACRS
ACRS
ALGN
ALGN
Q4 25
1.64×
Q3 25
3.33×
Q2 25
1.03×
Q1 25
0.57×
Q4 24
2.76×
Q3 24
2.27×
Q2 24
1.66×
Q1 24
0.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons